|
Cerebral Infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Altered Nurr1 protein expression in the hippocampal CA1 region following transient global cerebral ischemia.
|
31746417 |
2020 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, our bis-indole-derived NR4A2 antagonists represent a novel class of anti-cancer agents with potential future clinical applications for treating GBM.
|
31754919 |
2020 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, our bis-indole-derived NR4A2 antagonists represent a novel class of anti-cancer agents with potential future clinical applications for treating GBM.
|
31754919 |
2020 |
|
Anthrax disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we bacterially expressed and isolated a human Nurr1 fusion protein containing a N-terminal cell delivery domain derived from detoxified anthrax lethal factor followed by wild type ubiquitin with deubiquitinating enzyme recognition site for intracellular cleavage.
|
30121937 |
2019 |
|
Fatty Liver
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NURR1 expression in skeletal muscle is also sufficient to prevent hyperglycemia and hepatic steatosis, by enhancing muscle glucose uptake and storage as glycogen.
|
31110021 |
2019 |
|
Hyperglycemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NURR1 expression in skeletal muscle is also sufficient to prevent hyperglycemia and hepatic steatosis, by enhancing muscle glucose uptake and storage as glycogen.
|
31110021 |
2019 |
|
Morphine Dependence
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry showed that the number of TH⁺, Nurr1⁺, and Pitx3⁺ cells, and the number of TH⁺ cells expressing Nurr1 or Pitx3, significantly decreased in the VTA after a long period of morphine dependence.
|
30634592 |
2019 |
|
Mucocutaneous Lymph Node Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
After PCR validation, our data only revealed decreased NR4A2 mRNA expression in the KD patients compared to those of the controls, which increased after they received IVIG treatment.
|
30778379 |
2019 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings also identify NURR1 agonists as possible exercise mimetics with the potential to ameliorate obesity and other metabolic abnormalities.
|
31110021 |
2019 |
|
Laryngeal Squamous Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Among the known downstream genes of LMX1B, only NR4A2 expression showed a moderately negative correlation (Pearson's r = -0.54) with it in LSCC tissues.
|
31387183 |
2019 |
|
Sacculation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Structural insights into ligand-binding pocket formation in Nurr1 by molecular dynamics simulations.
|
30582418 |
2019 |
|
Impaired cognition
|
0.010 |
Biomarker
|
disease |
BEFREE |
Importantly, 5XFAD mice treated with amodiaquine, a highly selective synthetic Nurr1 agonist, showed robust reduction in typical AD features including deposition of Aβ plaques, neuronal loss, microgliosis, and impairment of adult hippocampal neurogenesis, leading to significant improvement of cognitive impairment.
|
30515963 |
2019 |
|
Inattention
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
However, the association between NURR1 defects and the attention-deficit hyperactivity disorder (ADHD), a DA-associated brain disease characterized by hyperactivity, impulsivity and inattention, has never been demonstrated.
|
31455763 |
2019 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The NR4A2 gene and cell-based therapy are described as promising drug candidates for neurodegenerative diseases.
|
30684217 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.010 |
Biomarker
|
disease |
BEFREE |
It is downregulated in peripheral blood mononuclear cells of MS patients; nonetheless, its role in MS has not been fully clear. miR-145-5p known as a putative regulator of NR4A2 and in a middle cerebral artery occlusion/reperfusion model, anti-miR-145-5p administration promoted neurological outcomes in rat.
|
30684217 |
2019 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.010 |
Biomarker
|
disease |
BEFREE |
It is notable that NR4A2 impairment is reversed in patients with RRMS during pregnancy, which represents a transitory state of immune tolerance, associated with reduced disease activity.
|
30565812 |
2019 |
|
Steatohepatitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NURR1 expression in skeletal muscle is also sufficient to prevent hyperglycemia and hepatic steatosis, by enhancing muscle glucose uptake and storage as glycogen.
|
31110021 |
2019 |
|
Epilepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Nurr1 enhances the drug resistance of epilepsy in rats by up-regulating the expression of proteins related to drug resistance.
|
29565514 |
2018 |
|
Pemphigus Vulgaris
|
0.010 |
Biomarker
|
disease |
BEFREE |
Regulatory effects of Nr4a2 on Th2 cells from patients with pemphigus vulgaris.
|
29541411 |
2018 |
|
Pervasive Development Disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
NR4A2 haploinsufficiency is associated with intellectual disability and autism spectrum disorder.
|
29770430 |
2018 |
|
Hormone refractory prostate cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Pairwise analysis identified five orphan NRs (including RORβ, TLX, COUP-TFII, NURR1 and LRH-1) that showed common upregulation in both mRNA and protein levels in the prostatospheroids and castration-relapse VCaP-CRPC xenografts, and overexpression of these orphan NRs could increase cancer stem cell marker expressions and enhance spheroid formation capacity in prostate cancer cells, suggesting that these orphan NRs might perform positive roles in the growth regulation of PCSCs and castration-resistant prostate cancer.
|
29042395 |
2018 |
|
Neurodevelopmental Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
We suggest that NR4A2 haploinsufficiency is implicated in neurodevelopmental disorder with high penetrance.
|
29770430 |
2018 |
|
Primary Myelofibrosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, we identified lymphoid enhancer-binding factor 1 (LEF1) and nuclear receptor subfamily 4, group A, member 2 (NR4A2) transcripts as miR-34a-5p-targets downregulated after miR-34a-5p overexpression in HPCs as well as in PMF CD34+ cells.
|
28098757 |
2017 |
|
Mild Mental Retardation
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our findings of a de novo deletion of NR4A2 in an individual with mild intellectual disability and prominent speech and language impairment provides further evidence for NR4A2 haploinsufficiency being causative for neurodevelopmental and particularly language phenotypes.
|
28544326 |
2017 |
|
Movement Disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Furthermore, Nurr1 overexpression remarkably relieved MPTP-induced movement disorder and spatial memory deficits and played neuroprotective and anti-inflammatory roles in MPTP-induced PD mice by down-regulating CCL2 in vivo.
|
27940361 |
2017 |